What is TIL Therapy? Tumor-Infiltrating Lymphocyte Treatment Explained

Understanding TIL Therapy in Simple Terms

Your immune system is your body's natural defense against disease. Inside many solid tumors, there are immune cells called T lymphocytes that have already recognized the tumor as a threat and entered the tumor to fight it. These are called tumor-infiltrating lymphocytes, or TILs.

The problem is that inside the tumor, these TILs are often overwhelmed by the tumor's defenses — they are outnumbered and exhausted. TIL therapy takes these cells out of the hostile tumor environment, multiplies them into a powerful army in the lab, and then reinfuses them back into your body to finish the fight.

Think of it this way: Your tumor already has special forces inside it fighting the cancer. TIL therapy takes those special forces out, gives them backup and reinforcements, and sends them back in to finish the job.

How TIL Therapy Works — Step by Step

The TIL therapy process involves several carefully coordinated steps, typically spanning 4-8 weeks from tumor collection to cell infusion.

Tumor Collection

A small sample of your tumor is surgically removed and sent to the lab.

Cell Isolation

TILs are extracted from the tumor tissue and identified in the lab.

Cell Expansion

The TILs are multiplied into billions of cells (4-6 weeks).

Cell Infusion

The TILs are infused back into your body to attack the cancer.

Why TIL Therapy is Different

TIL therapy differs fundamentally from other immunotherapies in several important ways:

Personalized: Each dose is custom-made from your tumor — not a one-size-fits-all drug.
Targets multiple antigens: TILs naturally recognize a broad range of tumor targets, making it harder for cancer to escape treatment.
Single infusion: Unlike checkpoint inhibitors that require continuous treatment, TIL therapy is typically a one-time infusion with durable responses that can last for years.
Effective in low-mutation tumors: TIL therapy works even in tumors with low mutational burden (like acral melanoma), where checkpoint inhibitors often fail.

GC101 — A Next-Generation TIL Therapy

GC101, developed by Juncell Therapeutics, represents a significant advancement over conventional TIL therapy. It is designed without the need for lymphodepletion conditioning chemotherapy and without high-dose IL-2 support — making it a safer and more accessible treatment option.

The clinical program for GC101 includes trials in non-small cell lung cancer (MIZAR-005), melanoma (MIZAR-003), and ovarian cancer (GC203), among other solid tumors.

Who Can Benefit?

TIL therapy is being studied in patients with advanced solid tumors who have progressed after standard treatment options have been exhausted. Current clinical trials are evaluating GC101 in:

Advanced non-small cell lung cancer (NSCLC)
Advanced melanoma (including acral and mucosal subtypes)
Recurrent ovarian cancer
Other solid tumors